Pfizer’s Celebrex Could Face Generic At-Risk Launches In May
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer had hoped to gain an extra 18 months of patent protection with a reissue patent granted last year but a district court ruled the method of use patent is invalid.